Drug facts
What the label says
Compounded tirzepatide has no label of its own. The label belongs to the approved products — Mounjaro and Zepbound, both from Eli Lilly — and everything below is drawn from it.
That distinction runs through every page here, because it is the most useful thing this section can tell you: what is established about tirzepatide was established about the approved product, and a compounded vial does not automatically inherit it.
- Pages in this corpus
- 21
- Sellers of the compounded version
- 402
- Approved products with a label
- 2
Taking it
- Dosage and titrationThe approved schedule: 2.5 mg to a maximum of 15 mg, in 2.5 mg steps no closer than four weeks apart.
- Units, milligrams and millilitersWhy a compounded vial is dosed in units on a syringe while every instruction is written in milligrams — and how the two relate.
- Storage and beyond-use datingThe label's refrigeration range and its 21-day room-temperature window, and why a compounded vial has a different kind of expiry.
- A missed doseWhat the label says to do, and the four-day rule that decides it.
- Injection sitesThe sites the label permits, and why rotation is specified.
- MicrodosingNot in the label at any dose below 2.5 mg, and not studied. What that absence does and does not mean.
Safety
- Side effects and how common they areThe reactions reported in 5% or more of trial participants, with the placebo rate beside each one.
- The boxed warningThe thyroid C-cell tumor warning, verbatim, and the contraindications that follow from it.
- Interactions with other medicinesOral drugs, contraceptives, and the hypoglycemia risk when combined with insulin or a sulfonylurea.
- Pregnancy and contraceptionWhy the label says to stop, and the four-week contraception window that reopens at every dose increase.
- BreastfeedingWhat section 8.2 of the label actually states.
What people report
- Hair lossA listed adverse reaction — with the trial rate and the placebo rate beside it.
- FatigueReported in 5 to 7% of participants against 3% on placebo.
- Muscle lossWhat weight loss does to lean mass, and what the label does and does not say about it.
- Anxiety and moodWhat both labels say, and the suicidality warning FDA had removed.
- AlcoholWhat the label addresses, and where it is silent.
- Obstructive sleep apneaWhere tirzepatide has been studied beyond weight and diabetes.
What you are buying
- Compounded tirzepatide vs ZepboundWhat is actually different: approval, labeling, concentration, and what evidence exists for each.
- How tirzepatide worksA dual GIP and GLP-1 receptor agonist, and what that dual action actually means.
- Is there an oral tirzepatide?No approved tirzepatide product is a tablet. What compounding sellers market as oral tirzepatide is something else — and Lilly's approved oral drug is a different molecule entirely.
- Mounjaro vs ZepboundSame molecule, two approvals. What actually differs.
Informational only. Nothing here is medical advice, and none of it replaces the judgment of a prescriber who knows your history.